Clinical Data ECO 2026: SURMOUNT-MAINTAIN proves tirzepatide sustains weight loss long term Pharmaceutical TechnologyAt ECO 2026, data from the SURMOUNT-MAINTAIN trial evaluating the use of Eli Lilly's Zepbound (tirzepatide) in sustaining weight loss was presented.Metabolic & GLP-1Read full story pharminent May 15, 2026 (Last updated: May 21, 2026) Pharmaceutical Technology At ECO 2026, data from the SURMOUNT-MAINTAIN trial evaluating the use of Eli Lilly’s Zepbound (tirzepatide) in sustaining weight loss was presented. Metabolic & GLP-1 Read full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: Trial miss doesn’t dent Biogen’s faith in Alzheimer’s drugNext: Kyowa Kirin secures FDA approval for Crysvita dosing update Related Stories Clinical Data Parsortix study shows promise for ADC target detection pharminent August 3, 2026 Clinical Data Novo setback casts doubt on a new way to treat heart disease pharminent July 31, 2026 Clinical Data Altimmune rises as GLP-1/GIP drug curbs heavy drinking in mid-stage study pharminent July 28, 2026
